

# Obsessive Compulsive Disorder Market to Exhibit Rapid Growth Rate From (2024-2034), Investigates DelveInsight

*The OCD market size was valued approximately USD 11,00 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034).*

LAS VEGAS, NEVADA, UNITED STATES, June 28, 2024 /EINPresswire.com/ -- DelveInsight's "Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Obsessive

Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the OCD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Obsessive Compulsive Disorder Market Forecast](#)

Some of the key facts of the Obsessive Compulsive Disorder Market Report:

The Obsessive Compulsive Disorder market size was valued approximately USD 11,00 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)

In 2022, there were approximately 12,082,000 prevalent cases of OCD across the 7MM. It is anticipated that these numbers will rise by the year 2034.

In the EU4 countries and the UK, Germany had the highest number of OCD cases, approximately ~2,121,000 in 2022, with expectations of an increase by 2034.

In 2022, Japan had approximately 2,150,000 prevalent cases of OCD, representing around 18% of the total OCD cases across the 7MM.



Obsessive Compulsive Disorder Market

In 2022, there were approximately 7,212,000 diagnosed cases of OCD across the 7MM. These cases are projected to rise by 2034.

In the UK, around 100,000 cases of OCD were prevalent among males and approximately 356,000 cases among females in 2022. These numbers are anticipated to rise by 2034.

In 2022, the lowest number of age-specific prevalent OCD cases were seen in individuals aged 60 and above, while the highest number of cases occurred in the 30–44 age group in France.

Key Obsessive Compulsive Disorder Companies: iohaven Pharmaceuticals, Inc., AbbVie, Biohaven Pharmaceuticals, Inc., AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Ortho-McNeil Janssen Scientific, Pfizer, and others

Key Obsessive Compulsive Disorder Therapies: Troriluzole, Fluvoxamine maleate, BHV-4157, Troriluzole, Quetiapine, Reclaim<sup>®</sup>, Bitopertin, topiramate, Escitalopram, Duloxetine, Topiramate, Paliperidone, pregabalin, and others

The Obsessive Compulsive Disorder epidemiology based on gender analyzed that the occurrence of gender-specific cases of OCD is more in females than in males

The Obsessive Compulsive Disorder market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Obsessive Compulsive Disorder pipeline products will significantly revolutionize the Obsessive Compulsive Disorder market dynamics.

#### Obsessive Compulsive Disorder Overview

Obsessive-compulsive disorder (OCD) is a widespread, persistent, and long-lasting mental illness in which a person experiences uncontrollable, recurrent thoughts (also known as "obsessions") and/or behaviours (sometimes known as "compulsions") that they feel the need to repeat.

Get a Free sample for the Obsessive Compulsive Disorder Market Report -

[https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market?utm\\_source=einpresswire&utm\\_medium=pressrelease&utm\\_campaign=gpr](https://www.delveinsight.com/report-store/obsessive-compulsive-disorder-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr)

#### Obsessive Compulsive Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

#### Obsessive Compulsive Disorder Epidemiology Segmentation:

The Obsessive Compulsive Disorder market report proffers epidemiological analysis for the

study period 2020–2034 in the 7MM segmented into:

Total Prevalence of Obsessive Compulsive Disorder

Prevalent Cases of Obsessive Compulsive Disorder by severity

Gender-specific Prevalence of Obsessive Compulsive Disorder

Diagnosed Cases of Episodic and Chronic Obsessive Compulsive Disorder

Download the report to understand which factors are driving Obsessive Compulsive Disorder epidemiology trends @ [Obsessive Compulsive Disorder Epidemiology Forecast](#)

Obsessive Compulsive Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Obsessive Compulsive Disorder market or expected to get launched during the study period. The analysis covers Obsessive Compulsive Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Obsessive Compulsive Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Obsessive Compulsive Disorder Therapies and Key Companies

Troriluzole: Biohaven Pharmaceuticals, Inc.

Fluvoxamine maleate: AbbVie

BHV-4157: Biohaven Pharmaceuticals, Inc.

Quetiapine: AstraZeneca

Reclaim®: MedtronicNeuro

Bitopertin: Hoffmann-La Roche

topiramate: Ortho-McNeil Pharmaceutical

Escitalopram: Forest Laboratories

Duloxetine: Eli Lilly and Company

Topiramate: Janssen-Ortho Inc

Paliperidone: Ortho-McNeil Janssen Scientific

pregabalin: Pfizer

Obsessive Compulsive Disorder Market Drivers

Negative lifestyle practices like unhealthy eating habits, smoking, lack of abundant sleep, and sedentary routine further proliferate anxiety disorders among individuals.

Even though the emerging pipeline for OCD is not robust, the expected approval of troriluzole, a

late-stage drug candidate with novel MoA, would drive the market.

## Obsessive Compulsive Disorder Market Barriers

SRIs, antipsychotics, mood stabilizers, and CBT are the mainstay of treatment for OCD. Therapies with novel MoAs are required to exhibit better efficacy and fewer side effects.

Although several clinical, environmental, and biological predictors of response have been reported, delivering more personalized treatments for OCD is not a reality thus far.

## Scope of the Obsessive Compulsive Disorder Market Report

Study Period: 2020–2034

Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

Key Obsessive Compulsive Disorder Companies: iohaven Pharmaceuticals, Inc., AbbVie, Biohaven Pharmaceuticals, Inc., AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Ortho-McNeil Janssen Scientific, Pfizer, and others

Key Obsessive Compulsive Disorder Therapies: Troriluzole, Fluvoxamine maleate, BHV-4157, Troriluzole, Quetiapine, Reclaim<sup>®</sup>, Bitopertin, topiramate, Escitalopram, Duloxetine, Topiramate, Paliperidone, pregabalin, and others

Obsessive Compulsive Disorder Therapeutic Assessment: Obsessive Compulsive Disorder current marketed and Obsessive Compulsive Disorder emerging therapies

Obsessive Compulsive Disorder Market Dynamics: Obsessive Compulsive Disorder market drivers and Obsessive Compulsive Disorder market barriers

Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

Obsessive Compulsive Disorder Unmet Needs, KOL's views, Analyst's views, Obsessive Compulsive Disorder Market Access and Reimbursement

To know more about Obsessive Compulsive Disorder companies working in the treatment market, visit @ [Obsessive Compulsive Disorder Clinical Trials and Therapeutic Assessment](#)

## Table of Contents

1. Obsessive Compulsive Disorder Market Report Introduction
2. Executive Summary for Obsessive Compulsive Disorder
3. SWOT analysis of Obsessive Compulsive Disorder
4. Obsessive Compulsive Disorder Patient Share (%) Overview at a Glance
5. Obsessive Compulsive Disorder Market Overview at a Glance
6. Obsessive Compulsive Disorder Disease Background and Overview
7. Obsessive Compulsive Disorder Epidemiology and Patient Population
8. Country-Specific Patient Population of Obsessive Compulsive Disorder
9. Obsessive Compulsive Disorder Current Treatment and Medical Practices
10. Obsessive Compulsive Disorder Unmet Needs
11. Obsessive Compulsive Disorder Emerging Therapies

12. Obsessive Compulsive Disorder Market Outlook
13. Country-Wise Obsessive Compulsive Disorder Market Analysis (2020–2034)
14. Obsessive Compulsive Disorder Market Access and Reimbursement of Therapies
15. Obsessive Compulsive Disorder Market Drivers
16. Obsessive Compulsive Disorder Market Barriers
17. Obsessive Compulsive Disorder Appendix
18. Obsessive Compulsive Disorder Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

#### About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Dr. Vishal Agrawal

DelveInsight Business Research

09193216187

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/723466788>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.